Advertisement

Special Populations: Protein Binding Aspects

  • Italo PoggesiEmail author
Living reference work entry

Abstract

The aim of this chapter is to provide a basic understanding of the effect of protein binding and its alterations on the pharmacokinetics of drugs and their pharmacological and clinical effects. This has been matter of controversies in the last decades: this chapter calls for scientific comprehension of the underlying phenomena and recommends a reasoned experimental program aiming to the characterization of the protein binding of new compounds and the effects of its changes in different conditions. Considerations and data are also reported concerning the potential changes of drugs’ protein binding in some pathophysiological conditions.

References and Further Reading

  1. Ascenzi P, Fanali G, Fasano M, Pallottini V, Trezza V (2014) Clinical relevance of drug binding to plasma proteins. J Mol Struct 1077:4–13CrossRefGoogle Scholar
  2. Benet LZ (2002) Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 71(3):115–121CrossRefGoogle Scholar
  3. Cheeti S, Budha NR, Rajan S, Dresser MJ, Jin JY (2013) A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer. Biopharm Drug Dispos 34:141–54CrossRefGoogle Scholar
  4. Chu CYT, Singla VP, Wang HP, Sweet B, Lai LTY (1981) Plasma α1-acid glycoprotein levels in pregnancy. Clin Chim Acta 112:235–240CrossRefGoogle Scholar
  5. DeVane L (2002) Clinical significance of drug binding, protei binding, and binding displacement drug interactions. Psychopharmacol Bull 36:5–21Google Scholar
  6. Everson G, Lasseter KC, Anderson KE, Bauer LA, Carithens RL, Wilner KD, Johnson A, Anziano RJ, Smolarek TA, Turncliff RZ (2000) The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function. Br J Clin Pharmacol 49:21–26CrossRefGoogle Scholar
  7. Grandison MK, Boudinot F (2000) D. Age-related changes in protein binding of drugs. Clin Pharmacokinet 38:271–290CrossRefGoogle Scholar
  8. Gugler R, Mueller G (1978) Plasma protein binding of valproic acid in healthy subjects and in patients with renal disease. Br J Clin Pharmacol 5:441–446CrossRefGoogle Scholar
  9. Hervé F, Urien S, Albengres E, Duché JC, Tillement JP (1994) Drug binding in plasma. Clin Pharmacokinet 26:44–58CrossRefGoogle Scholar
  10. Khosravan R, Grabowski BA, Mayer MD, Wu JT, Joseph-Ridge N, Vernillet L (2006) The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol 46:88–102CrossRefGoogle Scholar
  11. Kovarik JM, Sabia HD, Figueiredo J, Zimmermann H, Reynolds C, Dilzer SC, Lasseter K, Rordorf C (2001) Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. Clin Pharmacol Ther 70:425–30, 2001CrossRefGoogle Scholar
  12. Lau AH, Gustavson LE, Sperelakis R, Lam NP, El-Shourbagy T, Qian JX, Layden T (1997) Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function. Epilepsia 38:445–451CrossRefGoogle Scholar
  13. Loebstein R, Lalkin A, Koren G (1997) Pharmacokinetic changes during pregnancy and their clinical relevance. Clin Pharmacokinet 33:328–343CrossRefGoogle Scholar
  14. Lu H, Rosenbaum S (2014) Developmental pharmacokinetics in pediatric population. J Pediatr Pharmacol Ther 19:262–276PubMedPubMedCentralGoogle Scholar
  15. McNamara PJ, Alcorn J (2002) Protein binding predictions in infants. AAPS PharmSci 4:19–26CrossRefGoogle Scholar
  16. Mehvar R (2005) Role of protein binding in pharmacokinetics. Am J Pharm Educ 69:103CrossRefGoogle Scholar
  17. Muirhead GJ, Wilner K, Colburn W, Haug-Pihale G, Rouviex B (2002) The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil. Br J Clin Pharmacol 53:21S–30SCrossRefGoogle Scholar
  18. Musteata FM (2012) Calculation of normalized drug concentrations in the presence of altered plasma protein binding. Clin Pharm 51:55–68CrossRefGoogle Scholar
  19. Notarianni LJ (1990) Plasma protein binding of drugs in pregnancy and in neonates. Clin Pharmacokinet 18:20–36CrossRefGoogle Scholar
  20. Pang KS, Rowland M (1977) Hepatic clearance of drugs. II. Experimental evidence for acceptance of the “well-stirred” model over the “parallel tube” model using lidocaine in the perfused rat liver in situ preparation. J Pharmacokinet Biopharm 5:655–680CrossRefGoogle Scholar
  21. Peng JZ, Pulido F, Causemaker SJ, Li J, Lorenzo A, Cepeda C, Cabanillas JA, DaSilva B, Brun SC, Arribas J (2006) Pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus–coinfected subjects with hepatic impairment. J Clin Pharmacol 46:265–274CrossRefGoogle Scholar
  22. Roberts JA, Pea F, Lipman J (2013) The clinical relevance of plasma protein binding changes. Clin Pharmacokinet 52:1–8CrossRefGoogle Scholar
  23. Rolan PE (1994) Plasma protein binding displacement interactions – why are they still regarded as clinically important? Br J Clin Pharmacol 37:125–128CrossRefGoogle Scholar
  24. Rowland M, Tozer TN, Derendorf H, Hochhaus G (2011a) Clinical pharmacokinetics and pharmacodynamics: concepts and applications, 4th edn. Wolters Kluwer Health/Lippincott William & Wilkins, Philadelphia, p 98Google Scholar
  25. Rowland M, Tozer TN, Derendorf H, Hochhaus G (2011b) Clinical pharmacokinetics and pharmacodynamics: concepts and applications, 4th edn. Wolters Kluwer Health/Lippincott William & Wilkins, Philadelphia, p 75Google Scholar
  26. Rowland M, Tozer TN, Derendorf H, Hochhaus G (2011c) Clinical pharmacokinetics and pharmacodynamics: concepts and applications, 4th edn. Wolters Kluwer Health/Lippincott William & Wilkins, Philadelphia, p 100Google Scholar
  27. Rowland M, Tozer TN, Derendorf H, Hochhaus G (2011d) Clinical pharmacokinetics and pharmacodynamics: concepts and applications, 4th edn. Wolters Kluwer Health/Lippincott William & Wilkins, Philadelphia, p 388Google Scholar
  28. Schmidt S, Gonzalez D, Derendorf H (2010) Significance of protein binding in pharmacokinetics and pharmacodynamics. J Pharm Sci 99:1107–1122CrossRefGoogle Scholar
  29. Stangier J, Stähle H, Rathgen K, Roth W, Shakeri-Nejad K (2008) Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol 48:1411–1419CrossRefGoogle Scholar
  30. Verbeeck RK (2008) Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. In: European journal of clinical pharmacology, vol 64, pp 1147–1161Google Scholar
  31. Viani A, Rizzo G, Carrai M, Pacifici GM (1992) The effect of ageing on plasma albumin and plasma protein binding of diazepam, salicylic acid and digitoxin in healthy subjects and patients with renal impairment. Br J Clin Pharmacol 33:299–304CrossRefGoogle Scholar
  32. Wallace SM, Verbeeck RK (1987) Plasma protein binding of drugs in the elderly. Clin Pharmacokinet 12:41–72CrossRefGoogle Scholar
  33. Wilkinson GR, Shand DG (1975) A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18:377–390CrossRefGoogle Scholar
  34. Zhang F, Xue J, Shao J, Jia L (2012) Compilation of 222 drugs’ plasma prtein binding data and guidance for study design. Drug Discov Today 17:475–485CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Global Clinical PharmacologyQuantitative Sciences/Model-Based Drug DevelopmentCologno MonzeseItaly

Personalised recommendations